Haemonetics Corp (HAE) stock
Close on Nov 11, 2026Market cap $5.48BP/E 53.8Yield –
Haemonetics Corp grew revenue 4.1% to $1.38B over the twelve months to Sep 26, 2026. Operating income fell 27.1% to $176.95M, moving the operating margin from 18.3% to 12.8%. Free cash flow was $298.24M, up 16.5% from a year earlier. At the latest close the market valued the company at $5.48B, 53.8 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 26, 2026
Valuation
- Market cap
- $5.48B
- P/E ratio
- 53.8
- Price to sales
- 3.97
- Price to book
- 6.10
- Dividend yield
- –
- Free cash flow yield
- 5.44%
Fundamentals
- Revenue
- $1.38B
- Net income
- $103.91M
- EPS, diluted
- $2.24
- Free cash flow
- $298.24M
- Book value per share
- $19.34
- Diluted shares
- 46M
Trading
- Next earnings
- Feb 4, 2027 (estimated, before the open)
- Previous close
- $122.36
- Open
- $123.09
- Day's range
- $120.02 – $123.17
- Volume
- 390,243
- Average volume (20 days)
- 694,313
- Index membership
- S&P MidCap 400, Russell 2000 (since Jun 2021), Russell 3000
- Beta (5 years)
- 0.65
- 52-week range
- $51.00 – $132.00
- RSI (14 days)
- 55.1
- Volatility (1 year)
- 41.0%
- Relative volume
- 0.55×
- WACC
- 7.6%
On 1 of our idea list: Buyback cannibals
Index membership is inferred from the holdings of funds that track each index (IJH, SPMD, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | HAE | S&P 500 | Difference | HAE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +1.6% | -2.4% | +4.0 pts | ||
| 3 months | +38.2% | -1.2% | +39.4 pts | ||
| Year to date | +50.4% | +12.3% | +38.1 pts | ||
| 1 year | +68.0% | +12.4% | +55.6 pts | ||
| 3 years | +40.0% | +78.8% | −38.8 pts | +11.9% | +21.4% |
| 5 years | +104.2% | +75.2% | +29.0 pts | +15.3% | +11.9% |
| 10 years | +209.4% | +311.1% | −101.7 pts | +12.0% | +15.2% |
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Haemonetics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- News
About Haemonetics
Surgical & Medical Instruments & Apparatus
Haemonetics Corporation is a medical technology provider that supplies devices, software, and consumables to the healthcare sector. The company manages three primary segments: Plasma, Blood Center, and Hospital. Its Plasma division offers automated collection equipment and donor management software for source plasma facilities. The Blood Center unit provides automated apheresis systems to collect and process platelets, plasma, and red cells. Its Hospital segment delivers vascular closure devices, sensor-guided guidewires, esophageal protection tools, diagnostic hemostasis analyzers, surgical cell salvage systems, and transfusion management software. Customers comprise biopharmaceutical companies, blood collection centers, hospitals, group purchasing organizations, and health agencies.
Company profile, executives and historyHaemonetics stock: common questions
What is Haemonetics's stock price?
HAE closed at $120.54 on Nov 11, 2026, down 1.49% on the day. Over the past 52 weeks it traded between $51.00 and $132.00.
What is Haemonetics's market cap?
Haemonetics was worth $5.48B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is HAE's P/E ratio?
HAE trades at 53.8 times earnings, based on diluted earnings per share of $2.24 over the twelve months to Sep 26, 2026.
How much revenue does Haemonetics make?
Haemonetics reported revenue of $1.38B for the twelve months to Sep 26, 2026, up 4.1% from a year earlier.
Does Haemonetics pay a dividend?
No. Haemonetics has not paid a cash dividend over the last twelve months.
When does Haemonetics report earnings next?
Haemonetics is expected to report Q3 FY2027 results on Feb 4, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has HAE stock performed over the past year?
Including dividends, HAE returned +68.0% over the past year, against +12.4% for the S&P 500.
How many HAE shares are sold short?
4M shares were sold short at the latest FINRA report, 8.06% of the float, or 6.3 days of average trading volume.
Who are Haemonetics's competitors?
Companies most similar to Haemonetics by business, industry and size include IART, TFX, MMSI, PEN, ICUI.
See a number that looks wrong?